Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors.
Ma Y, Xue J, Zhao Y, Zhang Y, Huang Y, Yang Y, Fang W, Guo Y, Li Q, Ge X, Sun J, Zhang B, Zhang Y, Xiao J, Zhang L, Zhao H.
Ma Y, et al. Among authors: zhang l, zhang b, zhang y.
J Immunother Cancer. 2023 Jun;11(6):e006654. doi: 10.1136/jitc-2022-006654.
J Immunother Cancer. 2023.
PMID: 37263673
Free PMC article.
Clinical Trial.